Yuan et al. determined that DANCR upregulation was significantly associated with frequent tumor recurrence and cancer-related death and indicated that DANCR might be an attractive biomarker for risk prognostication, and that hepatocellular carcinoma (HCC) patients with DANCR overexpression should receive appropriate adjuvant therapies after hepatectomy (Yuan et al., 2016). The gene discussed is DANCR; the disease is hepatocellular carcinoma.